Merck Sharp & Dohme LLC
4,193
332
642
2,656
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
15.2%
637 terminated/withdrawn out of 4193 trials
80.7%
-5.8% vs industry average
30%
1253 trials in Phase 3/4
76%
2007 of 2656 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (4193)
Merck IIT: RRP Pembro and Lenvatinib
Role: collaborator
Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT
Role: collaborator
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Role: lead
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Role: lead
Single Dose Pharmacokinetics of Doravirine in HIV-infected Pregnant Women
Role: collaborator
Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics
Role: collaborator
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Role: lead
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Role: lead
Pembrolizumab in Locally Advanced Sinonasal Carcinoma
Role: collaborator
Study on PhArmacokinetics of First liNe Antiretrovirals in Healthy Breastfeeding Volunteers
Role: collaborator
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Role: collaborator
A Study of MK-8527 in Healthy Lactating Female Participants (MK-8527-009)
Role: lead
Spanish Decision Tool for Ovarian Cancer Maintenance Therapy
Role: collaborator
A Clinical Study of MK-4482 in Chinese Healthy Male Participants (MK-4482-009)
Role: lead
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Role: collaborator
Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)
Role: lead
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
Role: lead
PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma
Role: collaborator
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Role: collaborator
A Clinical Study of Ulonivirine (MK-8507) With Atorvastatin and Metformin in Healthy Adults (MK-8507-018)
Role: lead